Chemerin Versus Omentin-1 In Relation to Coronary Artery Disease in Obese Egyptian Patients
Abdelbassier, A., Soliman, A., Abdelhady, Y., Al-fakharany, R. (2024). Chemerin Versus Omentin-1 In Relation to Coronary Artery Disease in Obese Egyptian Patients. EKB Journal Management System, 5(3), 214-230. doi: 10.21608/ejmr.2023.230674.1445
Amira Rashad Abdelbassier; Ayman Saied Soliman; Yasser Ahmed Abdelhady; Reham S. Al-fakharany. "Chemerin Versus Omentin-1 In Relation to Coronary Artery Disease in Obese Egyptian Patients". EKB Journal Management System, 5, 3, 2024, 214-230. doi: 10.21608/ejmr.2023.230674.1445
Abdelbassier, A., Soliman, A., Abdelhady, Y., Al-fakharany, R. (2024). 'Chemerin Versus Omentin-1 In Relation to Coronary Artery Disease in Obese Egyptian Patients', EKB Journal Management System, 5(3), pp. 214-230. doi: 10.21608/ejmr.2023.230674.1445
Abdelbassier, A., Soliman, A., Abdelhady, Y., Al-fakharany, R. Chemerin Versus Omentin-1 In Relation to Coronary Artery Disease in Obese Egyptian Patients. EKB Journal Management System, 2024; 5(3): 214-230. doi: 10.21608/ejmr.2023.230674.1445

Chemerin Versus Omentin-1 In Relation to Coronary Artery Disease in Obese Egyptian Patients

Egyptian Journal of Medical Research
Volume 5, Issue 3, July 2024, Page 214-230  XML PDF (894.29 K)
Document Type: Original Article
DOI: 10.21608/ejmr.2023.230674.1445
View on SCiNiTO View on SCiNiTO
Authors
Amira Rashad Abdelbassier email 1; Ayman Saied Soliman1; Yasser Ahmed Abdelhadyorcid 2; Reham S. Al-fakharanyorcid 1
1Physiology department, Faculty of Medicine, Beni-suef University, Egypt
2cardiology department, Faculty of Medicine, Beni-Suef University, Egypt
Abstract
Background: The leading causes of mortality and disability globally are coronary artery disease and myocardial infarction, which is its primary consequence. Their growth is significantly influenced by lifestyle choices and the environment. These complicated illnesses also tend to run in families, which points to a significant hereditary component. Clear evidence of a molecular genetic link with coronary artery disease or myocardial infarction has yet to be found, despite significant investigation of several genes. Method: 75 patients were divided into 5 equal groups (control, obese ischemic, overweight ischemic, normal weight ischemic, and Obese noncardiac groups). According to BMI and the results of coronary angiography, patients will be included in one of the study groups mentioned above. Results: Omentin-1 is the highest in the control group and is the lowest in the obese cardiac group. Omentin-1 statistically significant differences existed between the groups. Omentin has; a strong negative correlation with BMI and CRP; a weak negative correlation with Age; a moderate negative correlation with coronary artery disease; no correlation with Lipid profile, Hb A1c, gender, and hypertension. Chemerin is the highest in the obese cardiac group and the lowest in the control group. Chemerin differences between groups were statistically significant, Chemerin has a strong positive correlation with BMI and CRP, a moderate positive correlation with Age and Coronary Artery Disease, a weak positive correlation with HB_A1C, and no correlation with Lipid profile, gender, or hypertension. Omentin-1 & Chemerin have a strong negative correlation between each other. Conclusion: plasma chemerin level was increased, while plasma omentin-1 level was decreased in obese patients with CAD, and they can be considered independent predictors of coronary artery disease in obese patients.
Keywords
Coronary artery disease; Chemerin; Omentin-1; BMI; and CRP
References
  1. Blüher, M. (2019): Obesity: global epidemiology and pathogenesis. Nature Reviews Endocrinology, 15(5), 288-298.‏
  2. Malakar AK, Choudhury D, Halder B, Paul P, Uddin A, Chakraborty S. A (2019): review on coronary artery disease, its risk factors, and therapeutics. J Cell Physiol;234(10):16812-16823.
  3. Farkhondeh, T., Folgado, S. L., Pourbagher-Shahri, A. M., Ashrafizadeh, M., & Samarghandian, S. (2020): The therapeutic effect of resveratrol: Focusing on the Nrf2 signaling pathway. Biomedicine & Pharmacotherapy, 127, 110234.‏
  4. Macvanin, M. T., Rizzo, M., Radovanovic, J., Sonmez, A., Paneni, F., & Isenovic, E. R. (2022): Role of Chemerin in Cardiovascular Diseases. Biomedicines, 10(11), 2970.‏
  5. Radzik-Zając, J., Wytrychowski, K., Wiśniewski, A., & Barg, W. (2022): The role of the novel adipokines vaspin and omentin in chronic inflammatory diseases. Pediatric Endocrinology Diabetes and Metabolism, 28(1).‏
  6. Garcia-Labbé D, Ruka E, Bertrand OF, Voisine P, Costerousse O, Poirier P. (2015): Obesity and coronary artery disease: evaluation and treatment. Can J Cardiol ;31(2):184-94.
  7. Yusuf, S., Joseph, P., Rangarajan, S., Islam, S., Mente, A., Hystad, P.,& Dagenais, G. (2020): Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. The Lancet, 395(10226), 795-808.
  8. Zhao, A., Xiao, H., Zhu, Y., Liu, S., Zhang, S., Yang, Z.,& Tian, Y. (2022): Omentin-1: a newly discovered warrior against metabolic related diseases. Expert Opinion on Therapeutic Targets, 26(3), 275-289. 10- El-Gaphar, O. A. M. A., Abo-Youssef, A. M., & Abo-Saif, A. A. (2018). Effect of losartan in complete freund’s adjuvant–induced arthritis in rats. Iranian Journal of Pharmaceutical Research: IJPR, 17(4), 1420.
  9. Léniz, A., González, M., Besné, I., Carr-Ugarte, H., Gómez-García, I., & Portillo, M. P. (2022): Role of chemerin in the control of glucose homeostasis. Molecular and Cellular Endocrinology, 541, 111504.
  10. Siegrist, M., Heitkamp, M., Braun, I., Vogg, N., Haller, B., Langhof, H., & Halle, M. (2021): Changes of omentin-1 and chemerin during 4 weeks of lifestyle intervention and 1-year follow-up in children with obesity. Clinical Nutrition, 40(11), 5648-5654.
  11. Baig, M., Alghalayini, K. W., Gazzaz, Z. J., & Atta, H. (2020): Association of serum omentin-1, chemerin, and leptin with acute myocardial infarction and its risk factors. Pakistan Journal of Medical Sciences, 36(6), 1183.
  12. Malakar AK, Choudhury D, Halder B, Paul P, Uddin A, Chakraborty S. A (2019): review on coronary artery disease, its risk factors, and therapeutics. J Cell Physiol;234(10):16812-16823.
  13. Mohammad, M. B., Sallam, A. S., Fekry, A. A., & Amin, M. I. (2021): Study of Omentin-1 and Chemerin as Predictors of Coronary Artery Disease in Elderly Patients, with Retrospective Studying of their Relation to Diabetes Mellitus Type 2. The Egyptian Journal of Hospital Medicine, 83(1), 995-1001.
  14. Quispe, R., Michos, E. D., Martin, S. S., Puri, R., Toth, P. P., Al Suwaidi, J.,& Elshazly, M. B. (2020): High‐Sensitivity C‐Reactive Protein Discordance With Atherogenic Lipid Measures and Incidence of Atherosclerotic Cardiovascular Disease in Primary Prevention: The ARIC Study. Journal of the American Heart Association, 9(3), e013600.
  15. Sell H, Laurencikiene J, Taube A, Eckardt K, Cramer A, Horrighs A, Arner P & Eckel J (2009):Chemerin is a novel adipocyte-derived factor inducing insulin resistance in primary human skeletal muscle cells. Diabetes 58 2731–2740.
  16. Szpakowicz, A., Kaminski, K. A., Szpakowicz, M., Lapinska, M., Paniczko, M., Lawicki, S., & Kowalska, I. (2020): Chemerin in coronary artery disease patients. European Heart Journal, 41(Supplement_2), ehaa946-1263.‏
  17. Özkan, E. A., Sadigov, A., & Öztürk, O. (2022): Evaluation of serum omentin-1, vaspin, leptin, adiponectin levels in obese/overweight children and their relationship with non-alcoholic fatty liver disease. Clinical Nutrition Research, 11(3), 194.‏
  18. Mirmajidi, S., Izadi, A., Saghafi-Asl, M., Vahid, F., Karamzad, N., Amiri, P., & Hébert, J. R. (2019): Inflammatory potential of diet: association with chemerin, omentin, lipopolysaccharide-binding protein, and insulin resistance in the apparently healthy obese. Journal of the American College of Nutrition, 38(4), 302-310.
 

Statistics
Article View: 203
PDF Download: 24